**Borrelia crocidurae**  
**Meningoencephalitis, West Africa**

Sandrine Goutier,1 Elisabeth Ferquel,1 Claudine Pinel, Annick Bosseray, Bruno Hoen, Gérard Couetdic, Amina Bourahoui, Claire Lapostolle, Hervé Pelloux, Martine Garnier, Natacha Sertour, Isabelle Pelloux, Patricia Pavese, and Muriel Cornet

Borrelia crocidurae–associated relapsing fever is endemic to West Africa and is considered benign. We report 4 patients with B. crocidurae–associated neurologic symptoms; 2 of their cases had been misdiagnosed. Frequency and severity of this disease could be underestimated; molecular methods and serodiagnostic tests for Lyme disease might be helpful in its detection.

Tick-borne relapsing fever (TBRF) is caused by several *Borrelia* species that are transmitted through the bites of *Ornithodoros* ticks (1). TBRF is an acute febrile illness characterized by multiple recurrences of nonspecific signs and symptoms, including fever, headache, myalgia, and arthralgia. Neurologic complications might occur, particularly related to *B. hispanica*, *B. crocidurae*, *B. duttoni*, and *B. turicatae* infections (2–7). Conventional diagnosis is made by microscopic detection of spirochetes in blood samples collected during acute febrile episodes and by direct examination of the cerebral spinal fluid (CSF) of patients with neurologic manifestations. Recently, molecular methods have been shown to be more reliable for *Borrelia* spp. detection in blood and CSF (3,8). *B. crocidurae* is endemic to West Africa; in Senegal, the rising incidence of infections reported recently has been associated with climate change (1,9). We report 3 cases of meningitis and 2 cases of encephalitis in 4 persons among a total of 11 consecutive travelers who returned from West Africa to France with *B. crocidurae* infections.

Author affiliations: Grenoble Teaching Hospital, Grenoble, France (S. Goutier, C. Pinel, A. Bosseray, H. Pelloux, I. Pelloux, P. Pavese, M. Cornet); Pasteur Institute, Paris, France (E. Ferquel, M. Garnier, N. Sertour), Joseph Fourier University, Grenoble (C. Pinel, H. Pelloux, M. Cornet); Besançon Teaching Hospital, Besançon, France (B. Hoen, G. Couetdic); Argenteuil Hospital, Argenteuil, France (A. Bourahoui); and Laennec Hospital, Quimper, France (C. Lapostolle)

DOI: http://dx.doi.org/10.3201/eid1902.121325

The Study

Persons included in our study had clinical signs and symptoms of meningitis or encephalitis, or both, and were selected from the 11 patients with cases of *B. crocidurae* TBRF that were reported to and confirmed by the National Reference Center for Borrelia (NRCB) in France during 2009–2011. The NRCB is the reference laboratory responsible for the epidemiologic surveillance of TBRF in France. Clinical meningitis or encephalitis was defined as previously reported (2). *Borrelia* species were detected in Giemsa-stained thin blood smears by microscopy and quantitativeuffy coat analysis (Becton Dickinson, Le Pont de Claix, France) when available (4). *Borrelia* spp. were detected and identified by using 16S rRNA PCR and subsequent sequencing as described (8). We tested serum and CSF samples with standardized antibody assays for detection of *Borrelia* spp. that cause Lyme disease (Table).

Among the 11 TBRF cases reported to NRCB during the 3-year study, we identified 4 (36%) cases of clinical meningitis or encephalitis, or both. The epidemiologic, clinical, and laboratory findings and the treatment of the 4 patients are documented in the Table. Three of the 4 patients were adult men, 26–57 years of age, and 1 was a 7-year-old girl. None of the patients were immunocompromised. They were all given appropriate antimarial agents without biological confirmation of *Plasmodium* infection.

At the time of admission to health care facilities, all patients had fever and headache. Patients 2, 3, and 4 had signs of meningitis, including neck stiffness; patients 2 and 4 also had phonophobia and photophobia. Patients 1 and 4 had encephalitis with drowsiness, which for patient 4 was accompanied by cerebellar syndrome (dysarthria and dysmetria). All patients except patient 3 underwent computed tomography scanning of the brain; no abnormality was detected. The 2 patients with encephalitis were examined by magnetic resonance imaging; in patient 4, a predominant positive contrast of the cerebellum leptomeninges on the right side was observed.

For all patients, 16S rRNA PCR and sequencing identified *B. crocidurae* (8) in blood samples. Laboratory analysis of the 4 CSF samples showed a lymphocytic pleocytosis, high protein concentrations, and a glucose value within reference range (Table). The molecular methods applied to CSF samples confirmed neurologic *B. crocidurae* infection in patients 1, 2, and 3. Serum samples collected from patients 1 and 4 at the time of diagnosis were tested by using Lyme disease serodiagnostic assays. ELISA detected substantial levels of IgM and IgG in samples from both patients; 1 was

---

1These authors contributed equally to this work.
Table. Epidemiologic, clinical, and laboratory findings and treatment for patients with *Borrelia crocidurae* meningoencephalitis

| Variables                                      | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|-----------------------------------------------|-----------|-----------|-----------|-----------|
| Demographic factor                            |           |           |           |           |
| Age, y/sex                                     | 36/M      | 57/M      | 7/F       | 26/M      |
| Country of origin/of residence                 | Senegal/| France/France | France/France | Senegal/France |
| Travel country                                 | Senegal  | Senegal   | Senegal   | Senegal   |
| Travel dates                                   | 2009 Mar–May | 2010 May | 2011 Feb–May | 2011 Aug–Sep |
| Travel duration, d                            | 53        | 15        | 15        | 35        |
| Travel accommodation                          | Family house | Hotel     | Hotel     | Family house |
| Arthropod or insect bite report                | No        | Yes       | No        | No        |
| Individual vector protection                   | No        | No        | No        | No        |
| First suspected diagnosis†/presumptive treatment | Malaria/quinine | Sinusitis | Gastroenteritis | Malaria/piperazine |
| Symptoms                                       |           |           |           |           |
| Oral temperature >38.5°C                       | Yes       | Yes       | Yes       | Yes       |
| Chills                                         | No        | No        | Yes       | Yes       |
| Total no. febrile episodes/no. before diagnosis | 2/1      | 4/2       | 6/5       | 2/1       |
| Length of acute febrile episodes, d            | 2–8       | 2–6       | 2         | 2–6       |
| Afebrile periods between febrile episodes, d   | 15        | 2–15      | 2–13      | 34        |
| Asthenia/anorexia/weight loss                  | Yes/no/no | Yes/yes/yes‡ | Yes/no/no | Yes/no/no |
| Headache                                      | Yes (severe) | Yes       | Yes (severe) | Yes (severe) |
| Myalgia                                       | No        | No        | No        | Yes       |
| Photophobia, phonophobia                      | No        | Yes       | No        | Yes       |
| Neck stiffness                                 | No        | Yes       | Yes       | Yes       |
| Cerebellar syndrome                           | No        | No        | No        | Yes       |
| Drowsiness                                    | Yes       | No        | Yes       | Yes       |
| Imaging results                                |           |           |           |           |
| Brain CT scan                                  | Normal    | Normal    | ND        | Normal    |
| Brain MRI                                     | Normal    | ND        | ND        | Abnormal  |
| Serologic results                              |           |           |           |           |
| Leukocytes, g/L                               | 4.7       | 15.8      | 13.0      | 8.4       |
| Hemoglobin, g/L                               | 134       | 139       | 115       | 131       |
| Platelets, g/L                                | 245       | 273       | 295       | 103       |
| C-reactive protein, mg/L                      | 103       | 4         | 57        | 150       |
| Creatinine, μmol/L                            | 107       | 76        | 42        | 99        |
| *Borrelia* spp. detection, Giemsa-stained blood smear | +§      | +§       | +§        | +¶        |
| Quantitative buffy coat                       | ND        | ND        | ND        | +         |
| ELISA anti–*B. burgdorferi* (titer)           | +11(1.3)  | ND        | ND        | +19       |
| Siemens Enzymnost Lyme link VlsE/IgG#         | ND        | ND        | ND        | +1(12.1)  |
| Siemens Enzymnost Borreliosis/IgM#            | +3.7      | ND        | ND        | +1(12.1)  |
| Western blot anti–*B. burgdorferi*            | +/–/+/+   | ND        | ND        | ND        |
| Bio-Advance IgG anti-VlsE/p31/p321#           | ND        | ND        | ND        | ND        |
| EUROIMMUN IgG anti-p17/p19/p21/p25/p30/p31/   | ND        | ND        | ND        | ND        |
| p39/p83/VlsE#                                 | ND        | ND        | ND        | ND        |
| Meridian Bioscience IgM garinii/afzelii/p41/p39/p17# | ND       | ND        | ND        | ND        |
| Bio-Advance IgM anti-p25/p83#                 | ND        | ND        | ND        | ND        |
| 16S RNA PCR *Borrelia* identification          | +/+       | ND        | ND        | ND        |
| CSF test results                               |           |           |           |           |
| Leukocytes, cells/mm³                          | 405       | 217       | 258       | 156       |
| % Lymphocytes                                 | 94        | 80        | 90        | 84        |
| Erythrocytes, cells/mm³                       | 0         | 7         | 12        | 5         |
| Protein, g/L                                  | 0.66      | 1.38      | 0.39      | 0.44      |
| Glucose, mmol/L                               | 3.1       | 2.7       | 2.69      | 2.9       |
| Chloride, mmol/L                              | 114       | 113       | 117       | 115       |
| Lactate, mmol/L                               | ND        | ND        | 1.5       | 2.2       |
| Direct examination (Gram stain)               | -         | -         | -         | -         |
| Conventional bacterial culture                | -         | -         | -         | -         |
| 16S RNA PCR *Borrelia* identification          | +/B. crociduae | +/B. crociduae | +/B. crociduae | +/B. crociduae |
| ELISA anti–*B. burgdorferi*                   | ND        | ND        | ND        | ND        |
| Siemens Enzymnost Lyme link VlsE/IgG#         | ND        | ND        | ND        | +††       |
| Siemens Enzymnost Borreliosis/IgM#            | ND        | ND        | ND        | −         |
| Treatment (daily dose/total d)                | Ceftriaxone (2 g/21) | Doxycycline (100 mg 2×d/10) | Ceftriaxone (2 g/14) | Doxycycline (100 mg 2×d/21) | ceftriaxone (2 g/15) |

*CT, computed tomography; MRI, magnetic resonance imaging; ND, not done; +, positive; −, negative; CSF, cerebrospinal fluid.
††First suspected diagnosis was not biologically confirmed.
‡‡††Average weight was 7 kg in 3 wk.
§§Second sample was positive.
¶¶First sample was positive after review prompted by the quantitative buffy coat result.
*Siemens, Erlangen, Germany; Bio-Advance, Bussy Saint Martin, France; EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany; Meridian Bioscience, Paris, France.
**Ambiguous.
†††1:12-fold dilution (low level).
confirmed by Western blot analysis. The CSF sample from patient 4 showed a low level of IgG (Table).

All cases were treated with doxycycline or ceftriaxone, or both (Table). In all patients, fever resolved within 3 days of the beginning of the appropriate treatment, and the outcomes were favorable. No Jarisch-Herxheimer reaction was observed.

*B. crocidurae*-associated TBRF is an emerging disease that is considered to be benign (1,9). However, the series of infections reported here suggest that severe neurologic complications, notably, meningitis and encephalitis, occur more frequently than previously thought and could be particularly common in travelers who acquired this infection in West Africa. For the patients we studied, the earliest neurologic signs occurred during the second febrile episode, confirming previous studies reporting the onset of neurologic complications after the first episode (2). However, facial palsy, often considered to be among the main clinical signs and symptoms of neuroborreliosis caused by TBRF-associated *Borrelia* species, was not observed in these patients (2). A similar clinical manifestation described in a recent case report of *B. crocidurae* encephalitis is entirely consistent with our observations (3).

Functional and experimental studies have focused on the capacity of TBRF-associated *Borrelia* species to cross the blood–brain barrier and to persist in the brain (2–7,10,11). These studies have established *B. crocidurae* as the most neurotropic species, an observation consistent with this and other case series and case reports. In animal models, this feature has been associated with the presence of vascular microemboli in the brain of infected animals and the particular ability of *B. crocidurae* to form and bind to erythrocyte rosettes, a phenomenon also involved in cerebral malaria pathogenesis. Erythrocyte aggregation might prevent host–pathogen interactions and thereby protect the spirochetes from the specific immune response (10,12,13).

The rather high frequency and severity of neurologic complications associated with *B. crocidurae* infection raise the problem of distinguishing it from cerebral malaria, because the areas of endemicity of these 2 diseases largely coincide (1,9). Indeed, relapsing fever is frequently misdiagnosed as malaria, as it was for 2 of the patients we studied, who were initially treated with antimalarial drugs (14). In this context, quantitative Buffy coat analysis that can effectively detect each pathogen in blood might be of particular interest (4). In addition, our study confirms the usefulness of molecular methods applied to blood and CSF samples to confirm *Borrelia* infection (3,8). The negative result obtained by PCR of CSF from patient 4 could have been the consequence of inappropriate storage of the sample at high room temperature for 72 hours before analysis.

Lyme disease serodiagnostic testing of serum and CSF samples might be helpful. Indeed, cross-reacting IgG and IgM were detected by ELISAs and in Western blot assays. Because Lyme disease is endemic to France, our results could have been caused by the actual detection of *B. burgdorferi* sensu lato antibodies, although none of the patients had a known history of Lyme disease.

No specific recommendations have been proposed for the treatment of patients with TBRF neuroborreliosis. Erythromycin and penicillin have been reported to be ineffective (5,6). In our series, all patients were prescribed either ceftriaxone or doxycycline, or both (Table), resulting in successful treatment of the disease. Thus, from the literature and our own experience, we suggest that TBRF with neurologic involvement should be treated with ceftriaxone or doxycycline for at least 21 days.

**Conclusions**

Our study highlights the frequent occurrence of meningitis or encephalitis in patients with *B. crocidurae* TBRF acquired in West Africa. The clinical and radiologic manifestations suggest that this infection could be more severe than previously thought. Consequently, travelers returning from West Africa with febrile neurologic disorders should be tested immediately for biological confirmation of *Borrelia* infection through blood and CSF analyses, including molecular methods.

**Acknowledgments**

We thank Laurence Courdavault, Patrick Plésiat, Ian Dorval, Jacques Croizé, and the technicians of the biology laboratory of the Centre Hospitalier d’Argenteuil for their help with diagnostic confirmation and for providing samples from the patients. We also thank Olivier Epaulard for his insightful comments on the manuscript.

Dr Goutier is an infectious disease specialist at the Groupe Hospitalier Mutualiste in Grenoble, France. Her research interests include clinical infectious diseases, antimicrobial drugs resistance, and epidemiology of nosocomial pathogens.

**References**

1. Cutler SJ, Abdissa A, Trape J-F. New concepts for the old challenge of African relapsing fever borreliosis. Clin Microbiol Infect. 2009;15:400–6. http://dx.doi.org/10.1111/j.1469-0691.2009.02819.x
2. Cadavid D, Barbour AG. Neuroborreliosis during relapsing fever: review of the clinical manifestations, pathology, and treatment of infections in humans and experimental animals. Clin Infect Dis. 1998;26:151–64. http://dx.doi.org/10.1086/516276
3. Bottieau E, Verbruggen E, Aubry C, Socolovsky C, Vlieghe E. Meningoencephalitis complicating relapsing fever in traveler returning from Senegal. Emerg Infect Dis. 2012;18:697–8. http://dx.doi.org/10.3201/eid1804.111771
4. van Dam AP, van Gool T, Wetssteyn JC, Dankert J. Tick-borne relapsing fever imported from West Africa: diagnosis by quantitative Buffy coat analysis and in vitro culture of *Borrelia crocidurae*. J Clin Microbiol. 1999;37:2027–30.
5. Colebunders R, De Serrano P, Van Gompel A, Wynants H, Blot K, Van den Enden E, et al. Imported relapsing fever in European tourists. Scand J Infect Dis. 1993;25:533–6. http://dx.doi.org/10.3109/00365549309008539
6. Nassif X, Dupont B, Fleury J, Lepresle C. Ceftiraxone in relapsing fever. Lancet. 1988;332:394. http://dx.doi.org/10.1016/S0140-6736(88)92860-7
7. Rodhain F. Borrelia et fièvres récurrentes: aspects épidémiologiques actuels. Bull Inst Pasteur. 1976;74:173–218.
8. Sarth M, Garnier M, Boudebourou N, Bouattour A, Rihani A, Hassar M, et al. Borrelia hispanica relapsing fever, Morocco. Emerg Infect Dis. 2009;15:1626–9. http://dx.doi.org/10.3201/eid1510.090403
9. Vial L, Diatta G, Tall A, Ba EH, Bouganali H, Durand P, et al. Incidence of tick-borne relapsing fever in west Africa: longitudinal study. Lancet. 2006;368:37–43. http://dx.doi.org/10.1016/S0140-6736(06)68968-X
10. Nordstrand A, Barbour AG, Bergström S. Borrelia pathogenesis research in the post-genomic and post-vaccine era. Curr Opin Microbiol. 2000;3:86–92. http://dx.doi.org/10.1016/S1369-5274(00)00056-9
11. Charmot G, Rodhain F, Dupont B, Sansonetti P, Lepresle C. Meningoencephalitis in a repatriate from Senegal. Think of borreliosis [in French]. Presse Med. 1986;15:979.
12. Shamaei-Tousi A, Martin P, Bergh A, Burman N, Brännström T, Bergström S. Erythrocyte-aggregating relapsing fever spirochete Borrelia crocidurae induces formation of microemboli. J Infect Dis. 1999;180:1929–38. http://dx.doi.org/10.1086/315118
13. Burman N, Shamaei-Tousi A, Bergström S. The spirochete Borrelia crocidurae causes erythrocyte rosetting during relapsing fever. Infect Immun. 1998;66:815–9.
14. Nordstrand A, Banikis I, Larsson C, Tsogbe K, Schwan TG, Nilsson M, et al. Tickborne relapsing fever diagnosis obscured by malaria, Togo. Emerg Infect Dis. 2007;13:117–23. http://dx.doi.org/10.3201/eid1301.060670

Address for correspondence: Sandrine Goutier, Service de Médecine Interne, Groupe Hospitalier Mutualiste de Grenoble, 8 Rue du Docteur Calmette, 38028 Grenoble Cedex 1, France; email: sandrinegoutier@hotmail.com